The regulator’s priority review and sBLA approval of the antibody were supported by data from Phase III and Phase II trials.

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

As per the latest analysis, the biosimilar and biologics market value is estimated to reach USD 520.9 billion in 2024. Global sales of biosimilars and biologics will likely increase at 7.6% CAGR ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2.